In:
Diabetes/Metabolism Research and Reviews, Wiley, Vol. 31, No. 3 ( 2015-03), p. 295-306
Abstract:
DA‐1229 is a novel, potent and selective DPP‐IV inhibitor that is orally bioavailable. In a pharmacodynamic study, more than 80% of DPP‐IV was inhibited by a single dose of 5 mg or higher of DA‐1229, and this level of inhibition was maintained for at least 24 h after a single dose of 10 mg or higher of DA‐1229. This phase II clinical trial was designed to evaluate the efficacy and safety of oral DA‐1229 and to determine the optimal dose to use for a phase III clinical study in Korean subjects with type 2 diabetes.
Type of Medium:
Online Resource
ISSN:
1520-7552
,
1520-7560
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2001565-3
Bookmarklink